ARDX Stock Price, Analysis & Fundamentals

Analysis

Ardelyx, Inc. is a healthcare company operating in the biotechnology industry. It has a market capitalization of $1.48 billion and generates revenue of $398.23 million on a trailing twelve-month (TTM) basis, employing 395 individuals. The company's financial health is marked by negative profitability metrics. The gross margin stands at 72.6%, while the operating margin is 4.2%. However, the profit margin is -14.2%. Ardelyx also reports net income of -$56,547,000 and EBITDA of -$35,298,000 on a TTM basis. Returns on equity and assets are -36.2% and -5.6%, respectively. The company's balance sheet shows $242.70 million in cash and $236.24 million in debt, resulting in a debt-to-equity ratio of 153.12. Ardelyx has a forward price-to-earnings (P/E) ratio of 30.82 and a price-to-book ratio of 9.59. The revenue growth rate is 12.3% year-over-year (YoY).

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Ardelyx, Inc.

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Visit website →

ARDX

Price History (1Y)

Analysis

About Ardelyx, Inc.

Key Statistics

Company Info